Cargando…

Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma

Introduction: This study aimed to identify immune mediators, including cytokines, chemokines, and growth factors, in the plasma for predicting treatment efficacy and immune-related adverse events (irAEs) in advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs). Methods...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shibata, Yosuke, Kishida, Takeshi, Kouro, Taku, Wei, Feifei, Igarashi, Yuka, Himuro, Hidetomo, Noguchi, Takeaki, Koizumi, Mitsuyuki, Suzuki, Takahisa, Osaka, Kimito, Saigusa, Yusuke, Sasada, Tetsuro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679331/ https://www.ncbi.nlm.nih.gov/pubmed/38026978 http://dx.doi.org/10.3389/fphar.2023.1269935

Ejemplares similares

Exhaustion of CAR T cells: potential causes and solutions
por: Kouro, Taku, et al.
Publicado: (2022)

Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report
por: Shibata, Yosuke, et al.
Publicado: (2021)

Evaluation of X-ray and carbon-ion beam irradiation with chemotherapy for the treatment of cervical adenocarcinoma cells in 2D and 3D cultures
por: Sekihara, Kazumasa, et al.
Publicado: (2022)

Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures
por: Wei, Feifei, et al.
Publicado: (2023)

Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy
por: Igarashi, Yuka, et al.
Publicado: (2020)

Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations
por: Iiizumi, Susumu, et al.
Publicado: (2019)

Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma
por: Suekane, Shigetaka, et al.
Publicado: (2017)

Diagnostic significance of reassessment of prostate biopsy specimens by experienced urological pathologists at a high-volume institution
por: Okubo, Yoichiro, et al.
Publicado: (2022)

Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin
por: Hashizume, Akihito, et al.
Publicado: (2018)

A lower psoas muscle volume was associated with a higher rate of recurrence in male clear cell renal cell carcinoma
por: Noguchi, Go, et al.
Publicado: (2020)

Clinicopathological Analysis of the ISUP Grade Group And Other Parameters in Prostate Cancer: Elucidation of Mutual Impact of the Various Parameters
por: Okubo, Yoichiro, et al.
Publicado: (2021)

Case of acute respiratory distress syndrome in a patient with an extragonadal germ cell tumor without lung metastasis in which choriocarcinoma syndrome was suspected
por: Kobayashi, Kota, et al.
Publicado: (2019)

PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer
por: Kawahara, Takashi, et al.
Publicado: (2018)

Astrocytes Protect Neurons against Methylmercury via ATP/P2Y(1) Receptor-Mediated Pathways in Astrocytes
por: Noguchi, Yusuke, et al.
Publicado: (2013)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Kumar, Utpal, et al.
Publicado: (2021)

Clinical importance of IL-22 cascade in IBD
por: Mizoguchi, Atsushi, et al.
Publicado: (2017)

Bilateral renal lymphoma: rapid recovery from an acute kidney injury after open renal biopsy
por: Mitome, Taku, et al.
Publicado: (2015)

Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
por: Kawahara, Takashi, et al.
Publicado: (2023)

Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
por: Tosev, Georgi, et al.
Publicado: (2021)

Fetal Lymphoid Progenitors Become Restricted to B-1 Fates Coincident with IL-7Rα Expression
por: Iida, Ryuji, et al.
Publicado: (2016)

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
por: Hattori, Saki, et al.
Publicado: (2023)

Urothelial ATP exocytosis: regulation of bladder compliance in the urine storage phase
por: Nakagomi, Hiroshi, et al.
Publicado: (2016)

Independent verification of circulating miRNA as diagnostic biomarkers for urothelial carcinoma
por: Urabe, Fumihiko, et al.
Publicado: (2022)

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
por: Stenehjem, David D, et al.
Publicado: (2018)

Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma
por: Tomiyama, Eisuke, et al.
Publicado: (2020)

Combination of Cisplatin and Irradiation Induces Immunogenic Cell Death and Potentiates Postirradiation Anti–PD-1 Treatment Efficacy in Urothelial Carcinoma
por: Fukushima, Hiroshi, et al.
Publicado: (2021)

The Relationship Between PD-1(rs2227981) and PD-L1(rs2890658) Polymorphisms and Urothelial Cell Carcinoma
por: Hlaing, Sa Tin Myo, et al.
Publicado: (2023)

Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine
por: Yutani, Shigeru, et al.
Publicado: (2013)

Src Homology 2–containing 5-Inositol Phosphatase (SHIP) Suppresses an Early Stage of Lymphoid Cell Development through Elevated Interleukin-6 Production by Myeloid Cells in Bone Marrow
por: Nakamura, Koji, et al.
Publicado: (2004)

Clinical evaluation of urine laminin‐γ2 monomer as a potent biomarker for non‐muscle invasive bladder cancer
por: Karashima, Takashi, et al.
Publicado: (2022)

Long-term survival of a patient with pulmonary metastatic urothelial carcinoma following metastasectomy
por: Hasebe, Kenichi, et al.
Publicado: (2018)

Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer
por: Sweis, Randy F., et al.
Publicado: (2018)

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
por: Wang, Li, et al.
Publicado: (2018)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
por: Faiena, Izak, et al.
Publicado: (2018)

Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis
por: Ding, Xiangli, et al.
Publicado: (2019)

Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer
por: Zeng, Dongqiang, et al.
Publicado: (2020)

Publisher Correction: Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
por: Tosev, Georgi, et al.
Publicado: (2021)

Investigation of tolerability and quality of life for carboplatin-based chemotherapy in an elderly urothelial carcinoma patient undergoing hemodialysis: a case report
por: Kondo, Masahiro, et al.
Publicado: (2018)

Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis
por: Liu, Junqi, et al.
Publicado: (2018)

A pilot study of gemcitabine and paclitaxel as third-line chemotherapy in metastatic urothelial carcinoma
por: Naiki, Taku, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_15k8nkcth034iugfstg0uu8f07